All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

verteporfin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
benzoporphyrin derivatives	2816	129497-78-5

Description:

Molecule	Description
Synonyms: verteporphin verteporfin trans-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester (1:1 mixture of two regioisomers) visudyne BPD-MA	A benzoporphyrin derivative that is used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION. Molecular weight: 1437.61 Formula: C82H84N8O16 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 173.56 ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
July 27, 2000	EMA
April 12, 2000	FDA	VALEANT LUXEMBOURG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	732.48	53.73	140	998	23270	90604039
Retinal haemorrhage	297.92	53.73	53	1085	5711	90621598
Choroidal neovascularisation	257.00	53.73	33	1105	374	90626935
Retinal pigment epithelial tear	188.93	53.73	24	1114	247	90627062
Polypoidal choroidal vasculopathy	169.49	53.73	19	1119	56	90627253
Subretinal fluid	111.69	53.73	17	1121	687	90626622
Disease progression	101.84	53.73	46	1092	156569	90470740
Retinal oedema	97.36	53.73	16	1122	1060	90626249
Detachment of retinal pigment epithelium	93.89	53.73	14	1124	491	90626818
Macular scar	78.30	53.73	10	1128	107	90627202
Retinal depigmentation	76.51	53.73	11	1127	298	90627011
Metamorphopsia	72.45	53.73	13	1125	1444	90625865
Vitreous haemorrhage	70.83	53.73	14	1124	2612	90624697
Maculopathy	65.41	53.73	13	1125	2493	90624816
Retinal pigment epitheliopathy	61.51	53.73	9	1129	276	90627033
Retinal degeneration	55.82	53.73	10	1128	1099	90626210

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	1082.78	114.03	222	1405	17328	42602380
Retinal haemorrhage	783.15	114.03	142	1485	5628	42614080
Choroidal neovascularisation	387.96	114.03	52	1575	241	42619467
Polypoidal choroidal vasculopathy	359.88	114.03	46	1581	134	42619574
Detachment of retinal pigment epithelium	296.15	114.03	45	1582	565	42619143
Disease progression	269.43	114.03	123	1504	143533	42476175
Retinal pigment epithelial tear	266.45	114.03	38	1589	296	42619412
Vitreous haemorrhage	240.73	114.03	47	1580	2700	42617008
Retinal degeneration	159.55	114.03	27	1600	686	42619022
Retinal detachment	138.71	114.03	35	1592	6490	42613218
Subretinal fibrosis	132.48	114.03	18	1609	93	42619615
Macular oedema	132.25	114.03	30	1597	3539	42616169

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	1756.03	58.73	341	2338	31832	110554788
Retinal haemorrhage	1005.38	58.73	177	2502	9324	110577296
Choroidal neovascularisation	668.45	58.73	86	2593	473	110586147
Polypoidal choroidal vasculopathy	530.55	58.73	64	2615	183	110586437
Disease progression	378.16	58.73	160	2519	243874	110342746
Detachment of retinal pigment epithelium	370.34	58.73	55	2624	950	110585670
Retinal pigment epithelial tear	358.43	58.73	49	2630	451	110586169
Vitreous haemorrhage	280.32	58.73	54	2625	4566	110582054
Subretinal fluid	216.57	58.73	36	2643	1308	110585312
Retinal oedema	196.10	58.73	34	2645	1593	110585027
Retinal degeneration	195.29	58.73	34	2645	1632	110584988
Retinal detachment	191.20	58.73	46	2633	11054	110575566
Subretinal fibrosis	171.13	58.73	23	2656	183	110586437
Macular oedema	168.28	58.73	38	2641	6928	110579692
Metamorphopsia	149.37	58.73	27	2652	1606	110585014
Retinal depigmentation	119.16	58.73	18	2661	348	110586272
Macular hole	107.14	58.73	19	2660	1012	110585608
Macular degeneration	100.25	58.73	32	2647	21627	110564993
Retinal pigment epitheliopathy	98.11	58.73	16	2663	514	110586106
Macular scar	97.92	58.73	13	2666	93	110586527
Maculopathy	92.32	58.73	20	2659	3007	110583613
Retinal disorder	91.36	58.73	19	2660	2351	110584269
Retinal exudates	90.25	58.73	17	2662	1267	110585353
Choroidal infarction	88.49	58.73	13	2666	206	110586414
Choroidal haemorrhage	74.09	58.73	11	2668	188	110586432
Retinal scar	71.34	58.73	12	2667	467	110586153
Visual field defect	64.06	58.73	19	2660	10053	110576567
Blindness	63.01	58.73	26	2653	36333	110550287

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01LA01	SENSORY ORGANS OPHTHALMOLOGICALS OCULAR VASCULAR DISORDER AGENTS Antineovascularisation agents
FDA PE	N0000009801	Photosensitizing Activity
FDA MoA	N0000010217	Photoabsorption
FDA EPC	N0000175540	Photoenhancer
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D011838	Radiation-Sensitizing Agents
MeSH PA	D017319	Photosensitizing Agents
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:47868	photosensitizing agent
CHEBI has role	CHEBI:66981	ophthalmology drug
CHEBI has role	CHEBI:88230	autophagy inhibitor

Related Drugs by ATC class:

S01LA Antineovascularisation agents 7 drugs

afliberceptanecortavebevacizumabbrolucizumabfaricimabpegaptanibranibizumab

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Choroidal retinal neovascularization	indication	75971007
Exudative age-related macular degeneration	indication	414173003	DOID:10873
Ocular histoplasmosis syndrome	indication	416770009
Pathologic Myopia	indication
Disease of liver	contraindication	235856003	DOID:409
Breastfeeding (mother)	contraindication	413712001
Porphyria	contraindication	418470004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4021216	VUID
N0000148662	NUI
D01162	KEGG_DRUG
4021216	VANDF
C0387288	UMLSCUI
CHEBI:32293	CHEBI
CHEMBL5314346	ChEMBL_ID
D000077362	MESH_DESCRIPTOR_UI
DB00460	DRUGBANK_ID
7145	INN_ID
0X9PA28K43	UNII
118886	RXNORM
31931	MMSL
8841	MMSL
d04533	MMSL
008219	NDDF
125708009	SNOMEDCT_US
387059006	SNOMEDCT_US
5362420	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Visudyne	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5600	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	26 sections
Visudyne	HUMAN PRESCRIPTION DRUG LABEL	1	24208-560	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	25 sections